Antibodies in sera from newly diagnosed insulin-dependent diabetes mellitus (IDDM) patients are directed to a human islet cell protein of relative molecular mass (Mr) 64,000. Since Il)DM seems to develop after a prodromal period of,8-cell autoimmunity, this study has examined whether 64,000 Mr antibodies could be detected in 14 individuals who subsequently developed IDDM and five first degree relatives who have indications of altered (3-cell function. Sera were screened by immunoprecipitation on total detergent lysates of human islets and positive sera retested on membrane protein preparations. Antibodies to the 64,000 Mr membrane protein were consistently detected in 11/14 IDDM patients, and in all 5 first degree relatives. 10 IDDM patients were already positive in the first samples, obtained 4-91 mo before the clinical onset of IDIM, whereas 1 patient progressed to a high 64,000 M, immunoreactivity, at a time where a commencement of a decline in (3-cell function was detected. 64,000 M, antibodies were detected before islet cell cytoplasmic antibodies (ICCA) in two patients. In the control groups of 21 healthy individuals, 36 patients with diseases of the thyroid and 5 SLE patients, the 64,000 Mr antibodies were detected in only one individual, who was a healthy sibling to an IDDM patient. These results suggest that antibodies against the Mr 64,000 human islet protein are an early marker of (-cell autoimmunity and may be useful to predict a later development of IDDM.
Introduction
The clinical onset of insulin-dependent diabetes mellitus (IDDM)' is associated with a specific loss of the H-cells in the 1. Abbreviations used in this paper: FBS, fasting blood sugar; FITC, fluoresceine isothiocyanate; ICCA, islet cell cytoplasmic antibodies; ICSA, islet cell surface antibodies; IDDM, insulin dependent diabetes mellitus; IVGTT, intravenous glucose tolerance test; NCS, newborn calf serum; NHS, normal human serum; OGTT, oral glucose tolerance test; PAGE, polyacrylamide gel electrophoresis; SLE, systemic lupus erythematosis; TBTE, 20 mM Tris/HCl (pH 7.4), 150 mM NaCl, 0.5 mM methionine, islets of Langerhans and autoimmune phenomena may play a role in the pathogenic process. A majority of newly diagnosed IDDM patients have islet cell surface antibodies (ICSA) and/or cytoplasmic antibodies (ICCA) (1) . Infiltrating lymphocytes are present in the pancreatic islets (2) and there is evidence for hypersensitivity towards pancreatic antigens (3) .
The nature of the primary (i-cell target antigen(s) remains to be elucidated. Immunoprecipitation of lysates of [35S]methionine labeled human islets showed that newly diagnosed diabetic children had antibodies to a relative molecular mass (Me) 64,000 protein (4) . In the spontaneously diabetic BB rat, which develops IDDM similar to the human disease, antibodies to a rat islet cell 64,000 Mr protein were also found to appear between 12 and 22 d of age (5, 6) , which is before the detection of both insulitis (around day 65) (7), decrease in 13- cell mass and function (day 45-50) (8, 9) and the subsequent onset of IDDM at or beyond 60-70 d of age.
IDDM in man seems to develop after a long latency period, which is reflected both in a decreased first-phase insulin release after intravenously administered glucose (10) (11) (12) (13) and in the appearance of ICCA (14) (15) (16) , which precedes the clinical onset of IDDM up to several years. Our hypothesis is that the 64,000 Mr protein is a primary target autoantigen. In this study we have therefore tested whether carefully documented individuals followed before their clinical onset of IDDM (10) (11) (12) (13) (14) (15) 17) and first degree relatives with signs ofimpaired (3-cell function, had 64,000
Mr antibodies. Control groups including healthy siblings to IDDM patients, healthy individuals with no family history of IDDM and patients with other autoimmune diseases were tested as well.
Methods
Isolation of islets. Human islets of Langerhans were isolated from the pancreata of 18 cadaver kidney donors at the University Hospitals of Copenhagen (male/female ratio 9:9, 14-60 yr ofage). HLA-typing showed HLA-DR 1 in 3, DR 2 in 6, DR 3 in 4, DR 4 in 4, DR 5 in 2, DR 6 in 3, and DR 7 in four pancreata. One pancreas was not tissue typed. Isolation of human islets by collagenase digestion and selection of individual islets under a stereomicroscope was carried out as described (18) . The islets were cultured for 1 d in RPMI 1640 medium supplemented with 0.35 g per liter NaHCO3, 20 mM Hepes, 10% (vol/vol) newborn calf serum (NCS), 100 U ml 1 penicillin and 100 ,g ml-' streptomycin. After being reselected and transferred individually to fresh medium supplemented with 0.5% normal human serum (NHS) instead of NCS, the islets were kept in culture (100 islets/4 ml) for 5-10 d. The release of insulin was measured by radioimmunoassay using porcine insulin (Nordisk Gentofte, Gentofte, Denmark) as standard.
Preparation oflabeled cell extracts. Cultured islets were washed twice by centrifugation (2 min, 200g) in methionine-free RPMI 1640 medium supplemented with 16 mM glucose, 2% NHS, penicillin, and streptomycin. Islets (500 islets/ml) were first incubated in this medium for 60 min before [35S]methionine (0.5 mCi/ml, New England Nuclear, Boston MA; > 500 Ci/mmol) was added. After incubation for 4-6 h at 370C, the labeled islets were harvested by centrifugation, washed twice in RPMI 1640 medium containing 0.5 mM methionine and once in TNMB buffer. The islets were resuspended (1,000 islets/ml) in TNMB supplemented with 1% Trasylol (Novo Industries, Bagsvord, Denmark), 5 mM EDTA and 0.1 mM p-chloromercuribenzenesulfonic acid (Sigma Chemical Co., St. Louis, MO) (TBTE buffer) and 1% Triton X-l 14 (TN-1 14) (Sigma Chemical Co.) precondensed as described by Bordier (19) . The suspension was incubated on ice for 2-4 h to solubilize the islets and then centrifuged at 100,000 g for 30 min. The lysate supernatant was either used for immunoprecipitation directly or after separation of amphiphilic membrane proteins from hydrophilic proteins by phase separation (19 (20, 100) , and lactalbumin (14, 400) .
Human sera. Sera were obtained from 14 IDDM patients (Table I ) who had been carefully studied before the clinical onset by being monozygotic twins or a monozygotic triplet (patients 1, 3, 6, 11, 12, 14 , and 5, respectively) (10, 11, 17) , or healthy siblings to IDDM patients (patients 2, 8, 9) (15 Furthermore sera were tested from one patient with atoxic diffuse and one patient with toxic adenom of the thyroid.
All sera were centrifuged at 10,000 g for 30 min, aliquoted and kept at -20'C. Coded sera from 5 monozygotic twins/triplets (P1, 3, 5, 11, 12) , 5 first degree relatives (R 1-5), 16 thyroiditis patients, and 3 controls (C8, 9, 14) were initially scored in a "blinded" fashion with the subject category assigned after analysis of the assay results.
Islet cell cytoplasmic antibodies. ICCA were analyzed in all the European patients and controls (Tables I-III) , using cryostat sections of human blood group 0 pancreata and a novel, highly sensitive two-color immunofluorescence assay with Texas from different patients were also tested in parallel and compared to positive and negative control sera. All serum samples were screened on total detergent lysates from at least two different islet preparations. Fig. 2 shows the immunoprecipitation ofcrude islet cell lysates using sera from IDDM patients 6, 7, 9, 13, and 14 (Fig. 2, lane K, Fig. 3, lanes B-E) , and one a weak (1+) 64,000 Mr component (Fig. 3, lane A) .
Analyses of64,000 M, antibodies in healthy individuals. This group was comprised of 10 healthy siblings ofthe IDDM patients included in this study, 6 healthy siblings to other IDDM patients, and 5 individuals without IDDM in the family (Table III) . Sera from a healthy sibling to patient 10 immunoprecipitated a very strong (3+) 64,000 Mr band from both crude 4ysates and TN-1 14 detergent phase purified proteins. This individual was tested and found to be positive for ICCA, but IVGTT showed no abnormalities. All other individuals in this group were Mr 64,000 antibody negative (Table III, Fig. 1, lanes C, D, G, H, Fig. 2, lanes A, B,  Fig. 3, lane F) .
Analyses of64,000 M, antibodies in serafrom SLE patients andpatients with diseases ofthe thyroid. Five SLE patients were tested and found to be negative for 64,000 Mr antibodies.
Sera from 16 Hashimoto's patients, 18 patients with Graves' disease, one patient with atoxic diffse, and one patient with toxic adenom were tested and found to be negative for 64,000 Mr antibodies. All these individuals were also tested for ICCA. Only one of these patients was ICCA positive. Immunoprecipitates with some sera containing high titers ofthyroid microsomal antibodies and crude human islet cell lysates had intensive background of nonspecifically precipitated proteins. Six ofthose sera immunoprecipitated a fuzzy band at a slightly lower Mr than the 64,000 protein band in the 64,000 Mr region (data not shown). However, prolonged gel electrophoretic analyses separated this band from the 64,000 Mr antigen, immunoprecipitated by IDDM sera. Furthermore, the sera were negative on TN-1 14 detergent phase purified-membrane proteins demonstrating that the protein they detected in crude lysates was not the 64,000 M, membrane protein immunoprecipitated by IDDM sera. These sera were tested in a group ofcoded sera and were scored negative on the basis of those analyses. Those results demonstrate the importance of using purified membrane proteins for 64,000 Mr antibody analyses to avoid false positives.
Prospective analysis of 64,000 Mr antibodies in IDDM patients. The 14 IDDM patients included in this study had been followed up to 4-91 mo before clinical onset of IDDM. Fig. 4 shows the 64,000 Mr antibody immunoreactivity and ICCA analyses in the observation period of each patient. Patients (Fig. 4, Table I ) (10, 11, 14) was the only 64,000 Mr antibody positive patient which progressed from a negative to 64,000 Mr antibody positive state during the observation period. When tested on total islet lysates, samples obtained 78 and 70 mo before the clinical onset were 64,000 Mr antibody negative. However, the latter sample showed a faint 64,000 Mr band when tested on TN-1 14 detergent phase purified islet proteins. The samples at 55 and 5 mo before the clinical onset were strongly 64,000 Mr antibody positive. The appearance of high 64,000 M, immunoreactivity in the 55-mo sample coincided with appearance of ICCA ( 11) and a commencement ofa slowly progressing decline in first-phase insulin release in response to intravenous glucose (10, 11, 14) .
Patient 2 (Fig. 4 , Table I [15]) was strongly positive, (3+), for 64,000 Mr antibodies, and ICCA 32 mo before and at the clinical onset ofIDDM. Fig. 1 shows immunoprecipitations using sera from this patient and two HLA-DR matched controls (DR 3, 4) on total lysates (lanes A-D) and TN-1 14 detergent phase purified membrane proteins (lanes E-H).
Patient 3 (Fig. 4 , Table I ) (1 1, 13, 14) was strongly positive, (3+), for 64,000 Mr antibodies 21 and 2 mo before the clinical onset. ICCA (1 1, 13, 14) was also positive.
Patient 4 (Fig. 4 , (Fig. 4, Table I ) (10, 11, 14) was strongly 64,000 Mr antibody positive, (2+), in a sample obtained 91 mo before clinical onset of IDDM, but became weakly positive in later samples. He was ICCA positive during the whole observation period (11) . Compared with his nondiabetic triplet mate, he showed a decrease of the first phase insulin release in response to intravenous glucose at 91 mo and a further progressive loss became apparent during the following years (10, 1 1).
Patient 6 (Fig. 4 , Table I ) (17) was strongly (2+) positive for 64,000 Mr antibodies already in the first sample (Fig. 2, and ICCA in samples obtained 4 mo before and at the clinical onset of IDDM (Fig. 2, lanes H, I ). Patient 8 (Fig. 4 , Patient 9 (Fig. 4 , Table 1 )2 was followed at regular intervals during a 1-yr period, starting 16 mo before the clinical onset of IDDM. 64,000 Mr antibodies were positive in samples 2-4, 7-10, while samples 1, 5, and 6 only immunoprecipitated a faint 64,000 Mr component (Fig. 2, lanes C-F) . All samples precipitated an additional strong band at 94,000 M, (Fig. 2, lanes   C-F) , which was detected as only a faint band in immunoprecipitates with other IDDM sera as well as control sera (Fig. 2,  lanes A, B, and G-M) TN-I 14 detergent phase purified-membrane proteins. This patient was positive for ICCA. in all but the last two samples. Patient 10 (Fig. 4 , Table I ) came to our attention due to intermittent glucosuria, hyperglycemia and impaired glucose tolerance during a febrile infection 25 mo before clinical onset ofIDDM. An oral glucose tolerance test showed impaired glucose tolerance. A 10,000-kJ diabetes diet was initiated, and the condition normalized. Fasting blood sugar was normal 2 wk later and remained within normal range during the rest of the observation period. IVGTT performed 8 mo later showed a total loss of first-phase insulin response. This patient was 64,000 Mr antibody negative but ICCA positive during the observation period.
Patient 11 (Fig. 4 , Table I ) (11, 14) was ICCA negative during the observation period. Sera obtained 12 and 1 mo before clinical onset of IDDM were negative when tested on total islet cell lysates. However, the first sample was weakly positive, when tested on TN-1 14 detergent phase purified islet cell proteins.
Patient 12 (Fig. 4 , Table I ) (11, 14) had been followed at 84, 72, and 48 mo before clinical onset of IDDM. 64,000 Mr antibodies were negative when the sera were tested on total islet cell lysates. The second serum sample was weakly positive, and the 94-67-C) C-) 25 22 first and third serum samples were negative, when tested on TN-114 detergent phase purified proteins.
Patient 13 (Fig. 4 , (Fig. 4, Table I ) was the only ICCA positive individual among 57 siblings to IDDM children in a Swedish family study. He was tested and found to be strongly 64,000 Mr antibody positive (Fig. 2, lane L) IVGTT showed a lowered /3-cell function. 25-mo later, when he developed clinical symptoms of IDDM and insulin was administered, he was still ICCA and 64,000 Mr antibody positive.
Correlation between ICCA and 64,000 M, autoantibodies.
Comparison of 64,000 Mr antibody and ICCA assays in individual patients (Fig. 4) shows that patients 1-9, and 14 were positive in assays for both 64,000 Mr antibodies and ICCA. Patients 10 and 13 were discordant; patient 10 was ICCA positive but 64,000 M, negative, and patient 13 was 64,000 Mr antibody positve and ICCA negative during the observation period. 64,000 M, antibodies were clearly detected before ICCA in patients 6 and 8. Patients 11 and 12 were negative or weakly positive in both assays indicating either that autoantibodies did not develop in these patients or that they were present earlier (patient 11) or later (patient 12) than the observation period. All 1st degree relatives (Table II) and controls, except one Hashimoto's disease patient, were concordant in both assays.
Discussion
Our results provide substantial evidence that antibodies to a 64,000 Mr human islet cell membrane protein (4) are associated with development of IDDM.
All IDDM patients included in this study except patient 10 had a family history of IDDM. In fact several of them had been followed before the clinical onset ofIDDM for that reason. This approach to study prodromal autoimmunity in IDDM was motivated by the fact that the prevalence of IDDM is only 0.4%. However, the majority of new patients (87%) has no IDDM family members.
In those highly selected individuals it was demonstrated that the 64,000 Mr antibodies preceded the clinical onset of IDDM by several years and sometimes even preceded the detection of ICCA.
The detection of 64,000 Mr antibodies several years before IDDM was clinically manifest lends support to the concept that an autoimmune attack on ,3-cells may start long before the clinical onset (25) . Experiments in mice indicate that a critical threshold of 80-90% loss of /-cells is needed before clinical symptoms of diabetes develop (26) . As described (11) (12) (13) 11 endocrine and nonendocrine human cell lines (27) , nor in freshly isolated human peripheral lymphocytes (4) and thyrocytes (S. Bawkkeskov, unpublished results) indicating that its expression may be restricted to islet cells. 64,000 Mr antibodies were detected in all (-cell specific, ICSA positive sera, tested on rat islets in a previous study (4) indicating that the protein is expressed in Y-cells. Furthermore, a protein of the same molecular mass has been specifically immunoprecipitated with IDDM sera from 13-cell tumors of transgenic mice (S. Bxkkeskov and D. Hanahan, unpublished results). An unequivocal assignment of the protein to human 13-cells requires analyses ofpurified human 13-cells and such material is presently not available.
The present data indicate that the 64,000 Mr protein antibodies may appear long before the clinical onset of IDDM. It is suggested that this component may represent the primary target protein in an autoimmune reaction against the Y-cells. A recent controlled trial with cyclosporin A suggests that the length and prevalence of remission in newly diagnosed IDDM patients are increased (28) . It is speculated that immune intervention may rather result in a prevention of IDDM if started before a major loss of :-cells has occurred. Therefore, a simple, reliable, and rapid assay using purified target autoantigen(s) are urgently needed to detect islet cell antibody positive persons who are potentially at risk of developing IDDM. We suggest that the 64,000 Mr protein may be a likely candidate for use in such assays.
